Meyrath et al., 2020 - Google Patents
The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptidesMeyrath et al., 2020
View HTML- Document ID
- 11845874696551571193
- Author
- Meyrath M
- Szpakowska M
- Zeiner J
- Massotte L
- Merz M
- Benkel T
- Simon K
- Ohnmacht J
- Turner J
- Krüger R
- Seutin V
- Ollert M
- Kostenis E
- Chevigné A
- Publication year
- Publication venue
- Nature communications
External Links
Snippet
Endogenous opioid peptides and prescription opioid drugs modulate pain, anxiety and stress by activating opioid receptors, currently classified into four subtypes. Here we demonstrate that ACKR3/CXCR7, hitherto known as an atypical scavenger receptor for …
- 239000003399 opiate peptide 0 title abstract description 100
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/566—Immunoassay; Biospecific binding assay using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meyrath et al. | The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides | |
Pandey et al. | Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors | |
Royal et al. | Migraine-associated TRESK mutations increase neuronal excitability through alternative translation initiation and inhibition of TREK | |
Harmeier et al. | Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers | |
Pradhan et al. | In vivo delta opioid receptor internalization controls behavioral effects of agonists | |
Munger et al. | Subsystem organization of the mammalian sense of smell | |
Zanin et al. | Interferon receptor trafficking and signaling: Journey to the cross roads | |
Walker et al. | Regulation of signal transduction by calcitonin gene-related peptide receptors | |
Bailey et al. | Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes | |
Roth et al. | Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation | |
Maurice et al. | GPCR-interacting proteins, major players of GPCR function | |
Koschatzky et al. | Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics | |
Hinkle et al. | Desensitization, trafficking, and resensitization of the pituitary thyrotropin-releasing hormone receptor | |
EP1662259A1 (en) | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases | |
TW200539867A (en) | Human g protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | |
Narita et al. | μ-Opioid receptor internalization-dependent and-independent mechanisms of the development of tolerance to μ-opioid receptor agonists: comparison between etorphine and morphine | |
US20100092974A1 (en) | Methods for screening for modulators of ccrl2 | |
Xiao et al. | “Barcode” and differential effects of GPCR phosphorylation by different GRKs | |
US20220273751A1 (en) | Gpcr heteromer inhibitors and uses thereof | |
Sadee | Ligand-free signaling of G-protein-coupled receptors: physiology, pharmacology, and genetics | |
Jong et al. | GPCR signaling from intracellular membranes | |
Doyle | Characterization of calcium regulated adenylyl cyclases | |
Meng et al. | BNP facilitates NMB-mediated histaminergic itch via NPRC-NMBR crosstalk | |
Gu et al. | Ligand-Dependent Mechanisms of CC Chemokine Receptor 5 (CCR5) Trafficking Revealed by APEX2 Proximity Labeling Proteomics | |
Arai et al. | Pharmacological lineage analysis revealed the binding affinity of broad-spectrum substance P antagonists to receptors for gonadotropin-releasing peptide |